IL-PROJECT44
30.4.2021 15:02:11 CEST | Business Wire | Press release
project44, the global leader in advanced visibility for shippers and logistics service providers will expand its real-time shipment tracking services in China – giving clients the same transportation visibility it offers across mature markets like North American and Europe. This expansion will focus the company’s resources on Asia-based visibility to fulfill its vision for global end-to-end visibility across all modes of transportation.
With logistics events in Asia continuing to send shockwaves across western markets, the opacity of Asia’s trucking markets has emerged as a weak link in global supply chains. As the economic recovery picks up pace, global supply chains are under pressure to improve agility, predictability, and efficiency.
At the same time, truckload markets in Asia have been modernizing rapidly as old trucks go out of service and China continues to incentivize the scrapping of old trucks. Newer trucks are equipped with electronic logging devices, paving the way to connect these trucks (with necessary data privacy provisions) to supply chain networks. These developments allow project44 to provide the foundational data needed to translate early indicators into important levers for supply chain resiliency.
Industry Support
The move by project44 to ramp up visibility in China has garnered broad support across the industry:
“Over the past year, Gartner has seen a dramatic increase in interest for Real-Time Transportation Visibility (RTTV) in the Asia Pacific,” said Bart A. De Muynck, Research Vice President, Transportation Technology at Gartner. “The sheer size of the Asia Pacific region combined with the diverse cultures spread across it creates unique challenges for transportation. Organizations that operate complex global supply chains often favor visibility solutions that can be implemented and utilized worldwide. project44 is recognized as a Leader by Gartner for its strong presence in both North America and Europe. Enterprise shippers that operate in Asia will benefit from project44’s expanded carrier coverage in China.”
“Building a more predictable global supply chain to increase on-time delivery and customer satisfaction is key to Lenovo’s business strategy,” said Renée Ure, Chief Operating Officer, Lenovo Infrastructure Solutions Group. “It’s critical to understand when materials are arriving from our suppliers to our factories across the world. project44’s expansion into the Asia Pacific region will give us further end-to-end visibility into our global supply chain to help us deliver on our promises to our customers.”
"CNHi is a truly global company in 180 countries. The recent state of global transportation has proven challenging, in part because it is difficult to manage our supply chains that span so many countries when disruption is high and visibility is so fragmented," said Dror Noach, Vice President of Global Logistics, CNH Industrial. "Gaining better visibility of both domestic and inbound flows going into our Asian manufacturing plants, especially China, could be quite beneficial for us. We believe project44's efforts to expand coverage in this region can help us improve assurance of supply and increase our efficiency."
Expanded Global Network Coverage
project44's best-in-class network already connects truckload carriers on every continent and nearly all containerized ocean freight moving between them, however, getting visibility into Asia’s trucking market remains a challenge for shippers. Its increased focus on Asian markets allows project44 to increase saturation outside of mature transportation markets and into Asia's ground transportation networks.
“At project44 we want to be wherever our customers need us, which means being connected to carriers all over the globe. For the first time ever, shippers can have a true global view of their supply chain network in a single platform,” said Jett McCandless, CEO and Founder of project44. “With our expansion into the Asia Pacific, we are considering the capabilities, regulations, and intricacies within each country which is key to delivering value to our current and future customers."
By expanding visibility in Asian markets, project44 will help buyers of Asian goods increase the resiliency of their supply chains. And in the process, project44 will extend visibility to domestic Asian shippers and logistics service providers who demand the same real-time transportation visibility enjoyed in western markets.
About project44
project44 solves some of the world’s most critical logistics challenges by connecting, automating, and providing real-time visibility into global transportation processes. With project44’s cloud-based platform, organizations can increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional, Amazon-like experience to their customers. project44 supports all transportation modes and shipping types, including air, parcel, final-mile, less-than-truckload, volume less-than-truckload, groupage, truckload, rail, intermodal, and ocean. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
